Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

822
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
822
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

23
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
23
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

188
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
188
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

696
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
696
Angina IV: Management01:26

Angina IV: Management

11
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chinese expert consensus on the choice of initial cholesterol-lowering strategy.

Frontiers in pharmacology·2026
Same author

Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance.

Clinical pharmacology and therapeutics·2024
Same author

2023 China Guidelines for Lipid Management.

Journal of geriatric cardiology : JGC·2023
Same author

New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients.

Lipids in health and disease·2018
Same author

New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.

Lipids in health and disease·2018
Same author

The eyes are the window to the heart: one case of cardiac amyloidosis with eyelid swelling as the initial symptom.

Journal of geriatric cardiology : JGC·2018

Related Experiment Video

Updated: Jul 16, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

2023 Chinese guideline for lipid management.

Jian-Jun Li1, Shui-Ping Zhao2, Dong Zhao3

  • 1National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Frontiers in Pharmacology
|September 15, 2023
PubMed
Summary

New Chinese guidelines for lipid management emphasize controlling low-density lipoprotein cholesterol (LDL-C) to prevent atherosclerotic cardiovascular disease (ASCVD). They recommend statins and lifestyle changes, with other medications for high-risk individuals.

Keywords:
atherosclerosiscardiovascular diseasecombined therapylipidmanagementstatin

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.0K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

Related Experiment Videos

Last Updated: Jul 16, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.0K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

Area of Science:

  • Cardiology
  • Public Health
  • Clinical Practice Guidelines

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death in China.
  • Elevated low-density lipoprotein cholesterol (LDL-C) is a significant risk factor for ASCVD.
  • The increasing burden of ASCVD necessitates updated lipid management strategies.

Purpose of the Study:

  • To revise and update the Chinese guidelines for lipid management.
  • To provide evidence-based recommendations for controlling LDL-C and preventing ASCVD.
  • To address varying target lipid levels based on individual ASCVD risk.

Main Methods:

  • Adaptation of existing dyslipidemia guidelines by an expert committee.
  • Incorporation of recent global research on blood lipids.
  • Risk stratification for determining target LDL-C levels.

Main Results:

  • Low-density lipoprotein cholesterol (LDL-C) remains the primary target for lipid control.
  • Cardiovascular disease (CVD) risk stratification is used to set LDL-C targets.
  • Initial treatment involves moderate-intensity statins and lifestyle modifications.
  • Additional therapies like PCSK9 inhibitors are recommended as needed.

Conclusions:

  • The new guidelines offer comprehensive lipid management strategies for all age groups.
  • They aim to improve clinical practice for ASCVD prevention and treatment.
  • Updated guidance is crucial given advancements in lipid research and the ASCVD burden.